Mursla Bio key facts
as of Oct 2026- Developer of a non-invasive diagnostic platform designed for the early detection of cancer.
- Mursla Bio is valued at approximately $53.2M as of Oct 2026 (last reported valuation).
- It has raised $10.2M; the latest was Later Stage VC ($2.2M) in Apr 2025.
- Notable investors include London & Partners., TA Ventures, Government of UK, Grow London.
- Status: Privately Held (backing).
Mursla Bio's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·Watch Mursla Bio: the Monday email on marks, rounds and moves
Mursla Bio funding rounds
No funding rounds for Mursla Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Mursla Bio
4Mursla Bio valuation
Mursla Bio's last reported valuation was $53.2 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
Mursla Bio investors
4 investors are on record for Mursla Bio, including London & Partners., TA Ventures, Government of UK and Grow London.
About Mursla Bio
Developer of a non-invasive diagnostic platform designed for the early detection of cancer. The company's platform applies extracellular vesicle science and omics analysis, incorporating organ-specific vesicle isolation from biofluids for precise targeting, an artificial intelligence-enabled workflow for disease biomarker identification, and a scalable assay system using optimal markers for clinical use, enabling healthcare providers to improve outcomes for at-risk patients.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2017
- Employees
- 17
- Website
- mursla.com/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.